Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer

Autophagy

Volumn 10, Issue 8, 2014, Pages 1478-1480

  Poklepovic, Andrew ^a   Gewirtz, David A ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Autophagy; Bortezomib; Hydroxychloroquine; Temozolomide; Temsirolimus; Vorinostat

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; HYDROXYCHLOROQUINE; LENALIDOMIDE; TEMOZOLOMIDE; TEMSIROLIMUS; VORINOSTAT; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BONE MARROW CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DRUG DOSE INTENSIFICATION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; GLIOBLASTOMA; HEMATOPOIESIS; HUMAN; MULTIPLE MYELOMA; MYELOMA; MYOPATHY; NEOPLASM; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; RETINOPATHY; SHORT SURVEY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYCHLOROQUINE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84905814994     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.29428     Document Type: Short Survey

References (8)

1. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res 2014; 74:647-51; PMID:24459182; http://dx.doi.org/10.1158/0008-5472. CAN-13-2966
2. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis L, Mita A, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined autophagy and HDAC inhibition: A phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10:1403-14; PMID:24991835; http://dx.doi.org/10.4161/auto.29231.
3. Rangwala R, Chang C, Hu J, Algazy K, Evans T, Fecher L, Schuchter L, Torigian DA, Panossian J, Troxel T. Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1391-1402; PMID:24991838; http://dx.doi.org/10.4161/auto.29119
4. Rangwala R, Leone R, Chang C, Fecher L, Schuchter LM, Kramer A, Tan K-S, Hetjian DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1369-79; PMID:24991839; http://dx.doi.org/10.4161/ auto.29118
5. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang C, Hu J, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10:1359-68; PMID:24991840; http://dx.doi.org/10.4161/auto.28984
6. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/ refractory myeloma. Autophagy 2014; 10:1380-90; PMID:24991834; http://dx.doi.org/10.4161/auto.29264
7. Kwon JB, Kleiner A, Ishida K, Godown J, Ciafaloni E, Looney RJ Jr. Hydroxychloroquine-induced myopathy. J Clin Rheumatol 2010; 16:28-31; PMID:20051753; http://dx.doi.org/10.1097/RHU.0b013e3181c47ec8
8. Stelton CR, Connors DB, Walia SS, Walia HS. Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 2013; 32:895-8; PMID:23515601; http://dx.doi.org/10.1007/s10067-013-2226-2